Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis

Clinical Rheumatology

Volumn 27, Issue 11, 2008, Pages 1429-1435

  Romero Sánchez, Consuelo ^a   Robinson, William H ^b   Tomooka, Beren H ^b   Londoño, John ^a   Valle Oñate, Rafael ^a   Huang, Feng ^c   Deng, Xiaohu ^c   Zhang, Liyun ^c   Yang, Chunhua ^c   Yu, David Tak Yan ^d  

^a UNIVERSIDAD DE LA SABANA   (Colombia)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ankylosing spondylitis; Biomarkers; Infliximab

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CYTOKINE; INFLIXIMAB; INTERLEUKIN 1ALPHA; STROMELYSIN;

ADOLESCENT; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG MONITORING; DRUG PULSE THERAPY; DRUG RESPONSE; ENZYME BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SYNOVIAL FLUID LEVEL; THROMBOCYTE COUNT;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; CASE-CONTROL STUDIES; CYTOKINES; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

EID: 53849090620     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-0941-x     Document Type: Article

References (21)

1. Sieper J, Rudwaleit M, Khan MA et al (2006) Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 20:401-417
2. McLeod C, Bagust A, Boland A et al (2007) Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: A systematic review and economic evaluation. Health Technol Assess 11:1-158
3. Anderson JJ, Baron G, van der Heijde D et al (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:1876-1886
4. Kim TH, Stone M, Payne U et al (2005) Cartilage biomarkers in ankylosing spondylitis: Relationship to clinical variables and treatment response. Arthritis Rheum 52:885-891
5. Maksymowych WP, Jhangri GS, Lambert RG et al (2002) Infliximab in ankylosing spondylitis: A prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29:959-965
6. Maksymowych WP, Landewe R, Conner-Spady B et al (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56:1846-1853
7. Rudwaleit M, Listing J, Brandt J et al (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63:665-670
8. Visvanathan S, Wagner CL, Marini JC et al (2007) Inflammatory biomarkers, disease activity, and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis, doi: 10.1136/ard.2007.071605
9. Zhu J, Yu DT (2006) Matrix metalloproteinase expression in the spondyloarthropathies. Curr Opin Rheumatol 18:364-368
10. Rao G (2003) What is an ROC curve? J Fam Pract 52:695
11. Huang F, Zhu J, Zhang L et al (2007) Response to one infusion predicts subsequent improvement as well as the rate of relapse of ankylosing spondylitis infused with three pulses of infliximab. Clin Rheumatol 26:920-926
12. Dixon JS, Martin MF, Bird HA et al (1983) A comparison of platelet count and acute phase proteins in the measurement of disease activity in rheumatoid arthritis. Br J Rheumatol 22:233-238
13. Milovanovic M, Nilsson E, Jaremo P (2004) Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta 343:237-240
14. Yang C, Gu J, Rihl M et al (2004) Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 51:691-699
15. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-368
16. Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286-2291
17. Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281-2285
18. Dougados M, van der Linden S, Juhlin R et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218-1227
19. Hueber W, Tomooka BH, Zhao X et al (2007) Proteomic analysis of secreted proteins in early rheumatoid arthritis: Anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 66:712-719
20. Kruithof E, De Rycke L, Vandooren B et al (2006) Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 54:1795-1804
21. Vandooren B, Kruithof E, Yu DT et al (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50:2942-2953